Sep. 9 at 3:57 PM
$RARE's gene therapy shows promise, but can it reverse the stock's decline?
RARE posted strong long-term data for its DTX401 therapy, reducing cornstarch intake by 61% in GSDIa patients and enhancing quality of life. Despite this, shares are down 25.1% YTD, underperforming the industry's 4.5% growth.
Full analysis here 👉 https://www.zacks.com/stock/news/2748856/rare-reports-positive-long-term-data-from-metabolic-disorder-study?cid=sm-stocktwits-2-2748856-body-11583&ADID=SYND_STOCKTWITS_TWEET_2_2748856_BODY_11583